Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kymera

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday released clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its oral STAT6 degrader medicine.

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Kymera Therapeutics Commences Initial-Stage Oncology Trials

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

Why Kymera Therapeutics Shares Are Falling Today

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ:KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). In…

JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474

JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ:KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says that the Company is "relatively insulated from downside pressure versus the benchmark from a healthy balance sheet." At the end of 2021, Kymera held approximately $567.6 million in cash, cash equivalents, and investments.…

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Organisations

European Medicines Agency

US Food and Drug Administration

Edwards Lifesciences

rapeutic Goods Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play